May 2025 FDA DRUG APPROVAL: Nuvaxovid – Strengthening Immunity, Protecting Lives! It is a protein-based, non-MRNA vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ✅ Indication: Approved for individuals 65 years and older and those 12-64 years with underlying conditions. ✅ Technology: Uses recombinant nanoparticle technology to mimic the spike protein of SARS-CoV-2. ✅ Efficacy: Proven safe and effective in preventing COVID-19. 🔴 Common Side Effects of Nuvaxovid 🔴 Like most vaccines, Nuvaxovid may cause mild to moderate side effects, which typically resolve within a few days. Here are some commonly reported reactions: 🔺 Injection Site Reactions: Pain, tenderness, redness, or swelling at the injection site. 🔺 General Symptoms: Fatigue, headache, muscle pain, and joint pain. 🔺 Flu-like Symptoms: Fever, chills, nausea, and vomiting. 🔺 Less Common Effects: Swollen lymph nodes, fainting, and inflammation-related conditions (e.g., myocarditis or pericarditis). Most side effects are temporary and indicate that the immune system is responding to the vaccine. However, if symptoms persist or worsen, consulting a healthcare professional is advised. Nuvaxovid offers a more traditional vaccine approach, making it an appealing option for those hesitant about newer mRNA technology. Become a part of our dynamic LinkedIn community to stay updated on the latest trends in publishing, research, and pharmaceutical webinars. Gain access to exclusive insights and opportunities that can enhance your career. Follow us today and embark on the SPSR journey with us! https://www.linkedin.com/company/spsr2010